Browse All

Current Filters

CLEAR FILTER x

TITLE

Non-ICANS Neurologic Toxicity Following Anti-BCMA Chimeric Antigen Receptor T Cell-therapy: Clinical Features and Outcomes

Author:Afzal, Saira   Anwer, Faiz   Khouri, Jack   Samaras, Christy   Shahzad, Raza   Mazzoni, Sandra   Cohen, Jeffrey   Kunchok, Amy   

Session Name:S30: Autoimmune Neurology: Clinical CNS Autoimmune and Inflammatory Disorders  

Topic:Autoimmune Neurology  

Program Number:S30.001  

Author Institution:Mellen Center for Multiple Sclerosis, Neurological Institute, Cleveland Clinic, Cleveland, OH  Cleveland Clinic Foundation, Cleveland, OH  

The Clinical Spectrum of patients with Discordant MOG-IgG Titers and MOGAD Diagnoses

Author:Havard, Katherine   Du, Mengke   Ontaneda, Daniel   Cohen, Jeffrey   Kunchok, Amy   

Session Name:P7: Autoimmune Neurology: NMOSD/MOGAD 6  

Topic:Autoimmune Neurology  

Program Number:P7.002  

Author Institution:Cleveland Clinic Foundation, Cleveland, OH  Cleveland Clinic, Cleveland, OH  Cleveland Clinic - Mellen Centre, Cleveland, OH  

Association of OCT Measures with Volumetric MRI in Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease (MOGAD)

Author:Samara, Amjad   Ongphichetmetha, Tatchaporn   Du, Mengke   Bernfeld, Eva Chava   Cohen, Jeffrey   Ontaneda, Daniel   Nakamura, Kunio   Kunchok, Amy   

Session Name:P7: Autoimmune Neurology: NMOSD/MOGAD 6  

Topic:Autoimmune Neurology  

Program Number:P7.004  

Author Institution:Cleveland Clinic , Cleveland Heights, OH  Cleveland Clinic , CLEVELAND, OH  Cleveland Clinic, Cleveland, OH  Cleveland Clinic , South Euclid, OH  Cleveland Clinic - Mellen Centre, Cleveland, OH  

Ofatumumab Treatment Up to Eight Years Shows a Favorable and Consistent Safety Profile in People Living With Relapsing Multiple Sclerosis

Author:Pardo, Gabriel   Montalban, Xavier   Cohen, Jeffrey   Morrow, Sarah   Li, Jun   Carr, David   Pearce, Gregory   Solonets, Maria   Abeyewickreme, Anil   de Seze, Jérôme   Nakahara, Jin   Wiendl, Heinz   Hauser, Stephen   

Session Name:P9: Multiple Sclerosis: Clinical Trials 2  

Topic:Multiple Sclerosis  

Program Number:P9.006  

Author Institution:Oklahoma Medical Research Foundation, Oklahoma City, OK, USA, Oklahoma City, OK  Department of Neurology/Neuroimmunology, Centre d’Esclerosi Múltiple de Catalunya (Cemcat), Hospital Universitari Vall d’Hebron, Barcelona, Spain, Barcelona, Spain  Department of Neurology, Mellen MS Center, Neurological Institute, Cleveland Clinic, Cleveland, OH, USA, Cleveland, OH  Hotchkiss Brain Institute, University of Calgary, Calgary, Alberta, Canada, calgary, AB, Canada  Novartis Pharma AG, Basel, Switzerland, Basel, Switzerland  IQVIA RDS GmbH, Frankfurt, Germany, Germany  Novartis Pharmaceuticals UK Ltd, London, United Kingdom, London, United Kingdom  University Hospital of Strasbourg, Strasbourg, France, Strasbourg, France  Department of Neurology, Keio University School of Medicine, Tokyo, Japan, Shinjuku-ku, Japan  Klinik für Neurologie und Neurophysiologie, Universitätsklinikum Freiburg, Freiburg, Germany, Freiburg im Breisgau, Germany  UCSF Weill Institute for Neurosciences, University of California, San Francisco, CA, USA, San Francisco, CA